Zachary Robert, M.D., Ph.D., Chief Medical Officer Oct. 12 | 5:45pm | UBC Ballroom   Dallas, TX  (NASDAQ: TIL)  In-person Presentation  Instil Bio is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer (solid tumors). Using an optimized and scalable...

Kenneth LaMontagne, Ph.D., Senior Vice President, Business Development Oct. 11 | 5:15pm | Oxford Biomedica Ballroom  New York, NY  (NASDAQ: INAB)  In-person Presentation  In8Bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Our platform employs allogeneic, autologous, and...

Xiaofang Wang, M.D., Ph.D., Chief Technology Officer  Oct. 12 | 9:30am | Oxford Biomedica Ballroom  Farmington, CT  (Private)  In-person Presentation  ImStem Biotechnology is an innovative biopharmaceutical company targeting areas in autoimmune, degenerative, and rare orphan diseases. With our state-of-the-art technology, we aspire to improve patient treatment outcomes and quality of health, as...

Steven Engle, CEO Oct. 11 | 5:30pm | Oxford Biomedica Ballroom   Dallas, TX  (Private)  In-person Presentation  Gradalis is a late-stage biotechnology company preparing to initiate a Phase III registration study in patients with ovarian cancer using a breakthrough immunotherapy platform. Based on multiple clinical studies, Gradalis has demonstrated that its immunotherapy...

Daniel Dornbusch, CEO  Oct. 13 | 11:30am | Oxford Biomedica Ballroom  San Francisco, CA  (Private)  In-person Presentation  Excision BioTherapeutics is a biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases. Excision unites next-generation CRISPR nucleases with a novel gene editing approach and has become the first and only...

David Millette, CEO and Chief Operating Officer  Oct. 11 | 11:00am | Oxford Biomedica Ballroom  Montreal, Canada  (Private)  In-person Presentation  ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with...

David McNinch, Chief Business Officer  Oct. 11 | 9:45am | Oxford Biomedica Ballroom  San Francisco, CA  (Private)  In-person Presentation  Encoded is a biotech company that engineers gene therapies to tackle challenging targets and diseases. Our research platform, driven on machine learning, targets cell specificity for greater selectivity and potency across many tissue...

Tony Ward, Chief Technology Officer Oct. 12 | 11:45am | Oxford Biomedica Ballroom   Carlsbad, CA  (Private)  In-person Presentation  Curate Biosciences (formerly GPB Scientific) enables cell processing that radically changes the outcomes and economics of cell therapy manufacturing. The Curate® Cell Processing System applies Deterministic Cell Separation™ (DCS) technology through a benchtop...

Rodolphe Clerval, CEO Oct. 12 | 1:30pm | Oxford Biomedica Ballroom   Paris, France  (Private)  In-person Presentation  Coave Therapeutics develops gene therapy products in CNS and ophthalmology based on a unique AAV-ligand platform for improved delivery of payloads in deep structures of the brain and the eye. We have three preclinical CNS programs with...

Matthew Lakelin, Ph.D., Co-founder and Vice President, Scientific Affairs and Product Development Oct. 13 | 10:15am | Oxford Biomedica Ballroom  Cardiff, UK  (Private)  In-person Presentation  TrakCel is the first provider of integrated cellular orchestration solutions for the precise management, control, and tracking of cell and gene therapy products. With the largest...

By using this website you agree to accept our Privacy Policy and Terms & Conditions